Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 692.50M | 687.80M | 673.30M | 684.10M | 744.60M | 714.80M |
Gross Profit | 374.10M | 381.30M | 379.70M | 394.20M | 379.90M | 390.60M |
EBITDA | -424.70M | -345.60M | 50.60M | 77.80M | 48.90M | -2.00M |
Net Income | -463.20M | -392.10M | -61.80M | 50.50M | 6.30M | -27.20M |
Balance Sheet | ||||||
Total Assets | 1.04B | 1.15B | 1.69B | 1.79B | 1.59B | 1.67B |
Cash, Cash Equivalents and Short-Term Investments | 90.30M | 107.70M | 87.70M | 127.70M | 118.50M | 111.50M |
Total Debt | 137.30M | 170.20M | 209.10M | 277.00M | 187.50M | 248.80M |
Total Liabilities | 262.70M | 325.70M | 456.10M | 495.70M | 330.70M | 416.30M |
Stockholders Equity | 776.30M | 828.50M | 1.24B | 1.29B | 1.26B | 1.26B |
Cash Flow | ||||||
Free Cash Flow | 87.90M | 82.90M | 14.60M | 71.60M | 66.30M | -22.70M |
Operating Cash Flow | 113.40M | 100.70M | 32.40M | 90.90M | 87.30M | -2.50M |
Investing Cash Flow | -41.90M | -27.50M | 21.60M | -135.40M | -21.00M | -24.20M |
Financing Cash Flow | -75.70M | -49.10M | -94.20M | 56.70M | -55.30M | -70.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | 533.28M | -27.19 | -4.72% | ― | -19.52% | 94.65% | |
57 Neutral | 508.79M | -3.69 | -29.10% | ― | -1.36% | -479.49% | |
54 Neutral | 584.52M | -4.53 | -26.99% | ― | 4.84% | 0.85% | |
53 Neutral | 569.66M | -913.51 | -0.10% | ― | 5.08% | 99.38% | |
52 Neutral | 473.64M | -10.03 | -11.75% | ― | 26.08% | -63.67% | |
49 Neutral | $561.47M | 45.80 | -46.17% | ― | 1.48% | -6091.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On September 15, 2025, Avanos Medical announced the acquisition of Nexus Medical, a company known for its TKO® anti-reflux needleless connector technology. This acquisition aims to enhance Avanos’ Specialty Nutrition Systems business by integrating Nexus’ technology, which supports safer nutrition and medication delivery in critical care settings like NICUs and PICUs. The acquisition is expected to immediately boost Avanos’ revenue growth and earnings per share, reinforcing its strategy to provide innovative solutions in critical care.
The most recent analyst rating on (AVNS) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Avanos Medical stock, see the AVNS Stock Forecast page.
On August 1, 2025, Avanos Medical appointed David Pacitti as a Board member and Scott Galovan as the Senior Vice President, Chief Financial Officer. The company reported a 1.9% increase in net sales for the second quarter of 2025, but faced a net loss of $76.8 million due to a $77.0 million goodwill impairment charge. Despite challenges, Avanos showed growth in its Specialty Nutrition Systems and Pain Management & Recovery segments, with strategic divestitures and restructuring efforts aimed at strengthening its market position.
The most recent analyst rating on (AVNS) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Avanos Medical stock, see the AVNS Stock Forecast page.